The Role of Direct Oral Anticoagulants in Managing Myeloproliferative Neoplasms Patients
Cancer Research and Treatment · 15.04.2025 · 57 (2) · 612-620
DOI: 10.4143/crt.2024.738 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.04.2025. Verfasst von Ji Yun Lee und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Anticoagulants, Venous Thromboembolism. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Seoul National University Bundang Hospital.
Abstract (Originalsprache)
Purpose
Thrombosis and bleeding significantly affect morbidity and mortality in myeloproliferative neoplasms (MPNs). The efficacy and safety of direct oral anticoagulants (DOACs) in MPN patients remain uncertain.Materials and Methods We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service database from 2010 to 2021.
Results
Out of the 368 MPN patients included in the final analysis, 62.8% were treated with DOACs for atrial fibrillation (AF), and 37.2% for venous thromboembolism (VTE). The AF group was statistically older with higher CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65-74 years, sex category [female]) scores compared to the VTE group. Antiplatelet agents were used in 51.1% of cases, and cytoreductive drugs in 79.3%, with hydroxyurea being the most common (64.9%). The median follow-up was 22.3 months, with 1-year cumulative incidence rates of thrombosis and bleeding at 11.1% and 3.7%, respectively. Multivariate analysis identified CHA2DS2-VASc scores ≥ 3 (hazard ratio [HR], 3.48), concomitant antiplatelet use (HR, 2.57), and cytoreduction (HR, 2.20) as significant thrombosis risk factors but found no significant predictors for major bleeding.
Conclusion
Despite the limitations of retrospective data, DOAC treatment in MPN patients seems effective and has an acceptable bleeding risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Förderung
- Seoul National University Bundang Hospital
Zitieren
APA
Lee, J. Y., Lee, J. H., Park, W., Seo, J., Kang, M., Jung, E. H., Kim, S. A., Suh, K. J., Kim, J. W., Kim, S. H., Lee, J. O., Kim, J. W., Kim, Y. J., Lee, K. W., Kim, J. H., & Bang, S. M. (2025). The Role of Direct Oral Anticoagulants in Managing Myeloproliferative Neoplasms Patients. Cancer Research and Treatment, 57(2), 612-620. https://doi.org/10.4143/crt.2024.738
Vancouver
Lee JY, Lee JH, Park W, Seo J, Kang M, Jung EH, et al. The Role of Direct Oral Anticoagulants in Managing Myeloproliferative Neoplasms Patients. Cancer Research and Treatment. 2025;57(2):612-620. doi:10.4143/crt.2024.738
BibTeX
@article{Lee2025,
author = {Lee, Ji Yun and Lee, Ju-Hyun and Park, Woochan and Seo, Jeongmin and Kang, Minsu and Jung, Eun Hee and Kim, Sang-A and Suh, Koung Jin and Kim, Ji-Won and Kim, Se Hyun and Lee, Jeong-Ok and Kim, Jin Won and Kim, Yu Jung and Lee, Keun-Wook and Kim, Jee Hyun and Bang, Soo-Mee},
title = {The Role of Direct Oral Anticoagulants in Managing Myeloproliferative Neoplasms Patients},
journal = {Cancer Research and Treatment},
year = {2025},
volume = {57},
number = {2},
pages = {612--620},
doi = {10.4143/crt.2024.738}
}
EUVIMED